Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYCC's Cash to Debt is ranked higher than
92% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CYCC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CYCC' s Cash to Debt Range Over the Past 10 Years
Min: 1  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.80
CYCC's Equity to Asset is ranked higher than
66% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYCC: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
CYCC' s Equity to Asset Range Over the Past 10 Years
Min: -3.51  Med: 0.76 Max: 0.88
Current: 0.8
-3.51
0.88
Interest Coverage No Debt
CYCC's Interest Coverage is ranked higher than
87% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYCC' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -16.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1022.09
CYCC's Operating margin (%) is ranked lower than
77% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. CYCC: -1022.09 )
Ranked among companies with meaningful Operating margin (%) only.
CYCC' s Operating margin (%) Range Over the Past 10 Years
Min: -25222.48  Med: -3591.39 Max: -1293.94
Current: -1022.09
-25222.48
-1293.94
Net-margin (%) -890.79
CYCC's Net-margin (%) is ranked lower than
77% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. CYCC: -890.79 )
Ranked among companies with meaningful Net-margin (%) only.
CYCC' s Net-margin (%) Range Over the Past 10 Years
Min: -19110.14  Med: -3470.22 Max: -936.62
Current: -890.79
-19110.14
-936.62
ROE (%) -67.05
CYCC's ROE (%) is ranked lower than
72% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CYCC: -67.05 )
Ranked among companies with meaningful ROE (%) only.
CYCC' s ROE (%) Range Over the Past 10 Years
Min: -198.89  Med: -102.58 Max: -42.99
Current: -67.05
-198.89
-42.99
ROA (%) -51.12
CYCC's ROA (%) is ranked lower than
69% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CYCC: -51.12 )
Ranked among companies with meaningful ROA (%) only.
CYCC' s ROA (%) Range Over the Past 10 Years
Min: -86.17  Med: -58.95 Max: -34.56
Current: -51.12
-86.17
-34.56
ROC (Joel Greenblatt) (%) -5204.55
CYCC's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CYCC: -5204.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYCC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -10207.43  Med: -2148.59 Max: -481.96
Current: -5204.55
-10207.43
-481.96
Revenue Growth (3Y)(%) -7.20
CYCC's Revenue Growth (3Y)(%) is ranked lower than
61% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CYCC: -7.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYCC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -12.90 Max: 37.5
Current: -7.2
0
37.5
EBITDA Growth (3Y)(%) -22.50
CYCC's EBITDA Growth (3Y)(%) is ranked lower than
74% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. CYCC: -22.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYCC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.4  Med: -32.25 Max: 14.1
Current: -22.5
-50.4
14.1
EPS Growth (3Y)(%) -25.20
CYCC's EPS Growth (3Y)(%) is ranked lower than
74% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CYCC: -25.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYCC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.8  Med: -30.15 Max: 19.3
Current: -25.2
-50.8
19.3
» CYCC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

CYCC Guru Trades in Q4 2014

Jim Simons 52,578 sh (New)
Wilbur Ross 58,158 sh (-50.00%)
» More
Q1 2015

CYCC Guru Trades in Q1 2015

Jim Simons Sold Out
Wilbur Ross Sold Out
» More
Q2 2015

CYCC Guru Trades in Q2 2015

Jim Simons 109,900 sh (New)
» More
Q3 2015

CYCC Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYCC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP4.0214.936% Convertible Exchangeable Preferred Stock

Ratios

vs
industry
vs
history
P/B 0.51
CYCC's P/B is ranked higher than
96% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. CYCC: 0.51 )
Ranked among companies with meaningful P/B only.
CYCC' s P/B Range Over the Past 10 Years
Min: 0.22  Med: 2.08 Max: 16.44
Current: 0.51
0.22
16.44
P/S 5.33
CYCC's P/S is ranked higher than
64% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. CYCC: 5.33 )
Ranked among companies with meaningful P/S only.
CYCC' s P/S Range Over the Past 10 Years
Min: 5.33  Med: 58.45 Max: 967.75
Current: 5.33
5.33
967.75
EV-to-EBIT 0.64
CYCC's EV-to-EBIT is ranked higher than
91% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 23.89 vs. CYCC: 0.64 )
Ranked among companies with meaningful EV-to-EBIT only.
CYCC' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.8  Med: -1.20 Max: 0.64
Current: 0.64
-4.8
0.64
EV-to-EBITDA 0.64
CYCC's EV-to-EBITDA is ranked higher than
91% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.19 vs. CYCC: 0.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYCC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5  Med: -1.20 Max: 0.64
Current: 0.64
-5
0.64
Current Ratio 5.09
CYCC's Current Ratio is ranked higher than
53% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CYCC: 5.09 )
Ranked among companies with meaningful Current Ratio only.
CYCC' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.09 Max: 12.96
Current: 5.09
0.96
12.96
Quick Ratio 5.09
CYCC's Quick Ratio is ranked higher than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CYCC: 5.09 )
Ranked among companies with meaningful Quick Ratio only.
CYCC' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.08 Max: 12.96
Current: 5.09
0.96
12.96
Days Sales Outstanding 438.21
CYCC's Days Sales Outstanding is ranked lower than
97% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CYCC: 438.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYCC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 728.32  Med: 1560.30 Max: 6980.27
Current: 438.21
728.32
6980.27

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.64
CYCC's Price/Net Cash is ranked higher than
97% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.23 vs. CYCC: 0.64 )
Ranked among companies with meaningful Price/Net Cash only.
CYCC' s Price/Net Cash Range Over the Past 10 Years
Min: 0.56  Med: 2.52 Max: 16.18
Current: 0.64
0.56
16.18
Price/Net Current Asset Value 0.52
CYCC's Price/Net Current Asset Value is ranked higher than
98% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 4.85 vs. CYCC: 0.52 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYCC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.46  Med: 2.31 Max: 7.58
Current: 0.52
0.46
7.58
Price/Tangible Book 0.52
CYCC's Price/Tangible Book is ranked higher than
97% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CYCC: 0.52 )
Ranked among companies with meaningful Price/Tangible Book only.
CYCC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.42  Med: 2.28 Max: 5.95
Current: 0.52
0.42
5.95
Price/Median PS Value 0.09
CYCC's Price/Median PS Value is ranked higher than
97% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. CYCC: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
CYCC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 1.03 Max: 16.39
Current: 0.09
0.13
16.39
Earnings Yield (Greenblatt) (%) 156.00
CYCC's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CYCC: 156.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYCC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 156  Med: 362.20 Max: 25664.1
Current: 156
156
25664.1

More Statistics

Revenue(Mil) $2
EPS $ -0.58
Beta4.68
Short Percentage of Float0.98%
52-Week Range $0.30 - 2.13
Shares Outstanding(Mil)34.70

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 2 2 2 12
EPS($) -0.45 -0.49 -0.73 -0.72
EPS without NRI($) -0.45 -0.49 -0.73 -0.72

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UXI2.Germany,
Cyclacel Pharmaceuticals Inc was founded in August 13, 1996 and is incorporated in Delaware. The Company is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Its clinical development priorities are focused on sapacitabine only, its second drug candidate, seliciclib, is a novel, orally-available, CDK clinical development priorities are focused on sapacitabine as an orphan drug for the treatment of both Acute Myeloid Leukemia, or AML, and Myelodysplastic Syndromes, or MDS. The Company is currently evaluating sapacitabine in a Phase 3 study being conducted under a Special Protocol Assessment, or SPA, with the FDA for the front-line treatment of AML in the elderly. The Company is also exploring sapacitabine in Phase 2 studies for MDS, non-small cell lung cancer, or NSCLC, and chronic lymphocytic leukemia, or CLL and in a Phase 1 study in solid tumors in combination with seliciclib, another of its drug candidates. Sapacitabine has been evaluated in approximately 1,000 patients to date. In addition, in polo-like kinase, or PLK inhibitor program, the Company has discovered CYC140 and other small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. The Company retains all marketing rights for these compounds internationally.
» More Articles for CYCC

Headlines

Articles On GuruFocus.com
Wilbur Ross Buys Two New Stakes in First Quarter Jun 15 2015 
Insider Cluster Buying Reported in Several Companies May 30 2013 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
4:21 pm Cyclacel Pharma has not regained compliance with $1.00 min bid requirement to remain listed... Feb 07 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 05 2016
Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing Feb 05 2016
Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference Feb 02 2016
Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 Jan 11 2016
Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 Jan 11 2016
Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast... Jan 07 2016
Value Strategies in 2015: NCAV up 30%, Destruction for the others Jan 06 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Dec 31 2015
Molecular Basis for Development of Cyclacel’s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast... Dec 14 2015
CYCLACEL PHARMACEUTICALS, INC. Financials Dec 08 2015
Cyclacel Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 07 2015
CYC065, Cyclacel’s Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models Nov 23 2015
Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results Nov 12 2015
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 12 2015
Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results Nov 12 2015
Q3 2015 Cyclacel Pharmaceuticals Inc Earnings Release - Time Not Supplied Nov 12 2015
Mechanistic Rationale for CYC065, Cyclacel’s CDK2/9 Inhibitor, in Targeted Solid Tumors and... Nov 09 2015
Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results Nov 05 2015
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Oct 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK